Indaptus Therapeutics, Inc

This early-stage study is testing a new immunotherapy drug called DECOY20, both alone and combined with another cancer drug (tislelizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses, check for s…